PL1948789T3 - Sposób wytwarzania ciągłych ludzkich linii komórkowych - Google Patents

Sposób wytwarzania ciągłych ludzkich linii komórkowych

Info

Publication number
PL1948789T3
PL1948789T3 PL06818078T PL06818078T PL1948789T3 PL 1948789 T3 PL1948789 T3 PL 1948789T3 PL 06818078 T PL06818078 T PL 06818078T PL 06818078 T PL06818078 T PL 06818078T PL 1948789 T3 PL1948789 T3 PL 1948789T3
Authority
PL
Poland
Prior art keywords
production
human cell
cell lineages
permanent human
expression
Prior art date
Application number
PL06818078T
Other languages
English (en)
Inventor
Gudrun Schiedner
Christoph Volpers
Original Assignee
Cevec Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cevec Pharmaceuticals Gmbh filed Critical Cevec Pharmaceuticals Gmbh
Publication of PL1948789T3 publication Critical patent/PL1948789T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/06—Uses of viruses as vector in vitro

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
PL06818078T 2005-11-16 2006-11-15 Sposób wytwarzania ciągłych ludzkich linii komórkowych PL1948789T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005054628A DE102005054628A1 (de) 2005-11-16 2005-11-16 Verfahren zur Herstellung von permanenten humanen Zelllinien
EP06818078A EP1948789B1 (de) 2005-11-16 2006-11-15 Verfahren zur herstellung von permanenten humanen zelllinien
PCT/DE2006/002004 WO2007056994A2 (de) 2005-11-16 2006-11-15 Verfahren zur herstellung von permanenten humanen zelllinien

Publications (1)

Publication Number Publication Date
PL1948789T3 true PL1948789T3 (pl) 2010-11-30

Family

ID=37770340

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06818078T PL1948789T3 (pl) 2005-11-16 2006-11-15 Sposób wytwarzania ciągłych ludzkich linii komórkowych

Country Status (19)

Country Link
US (2) US8936908B2 (pl)
EP (1) EP1948789B1 (pl)
JP (1) JP5213719B2 (pl)
KR (1) KR101244529B1 (pl)
CN (1) CN101310014B (pl)
AT (1) ATE470702T1 (pl)
AU (1) AU2006314931B2 (pl)
CA (1) CA2629211C (pl)
CY (1) CY1110734T1 (pl)
DE (2) DE102005054628A1 (pl)
DK (1) DK1948789T3 (pl)
ES (1) ES2345508T3 (pl)
IL (1) IL190705A (pl)
MY (1) MY144034A (pl)
PL (1) PL1948789T3 (pl)
PT (1) PT1948789E (pl)
SG (1) SG173947A1 (pl)
SI (1) SI1948789T1 (pl)
WO (1) WO2007056994A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
DE102009003439A1 (de) * 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
CN101942413B (zh) * 2009-07-07 2015-02-11 翁炳焕 出生缺陷细胞库及其构建方法
JP5928843B2 (ja) * 2010-08-16 2016-06-01 ツェヴェック ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング インフルエンザウイルスを製造するための永久ヒト羊膜細胞株
EP2722337A1 (en) * 2012-10-19 2014-04-23 CEVEC Pharmaceuticals GmbH Production of a HCMV based vaccine in human amniocyte cell lines
EP2909228A1 (en) * 2012-10-19 2015-08-26 CEVEC Pharmaceuticals GmbH Production of a hcmv based vaccine in human amniocyte cell lines
WO2014115087A2 (en) 2013-01-22 2014-07-31 Cencor Biotech Ltd. A method for the preparation of recombinant human prothrombin and fibrinogen
EP3154694A1 (en) 2014-06-13 2017-04-19 Children's Medical Center Corporation Products and methods to isolate mitochondria
KR20170141217A (ko) 2015-05-12 2017-12-22 상가모 테라퓨틱스, 인코포레이티드 유전자 발현의 뉴클레아제-매개된 조절
PT3294764T (pt) * 2015-05-15 2021-02-15 Hope City Composições de recetores de antigénios quiméricos
WO2017095946A1 (en) 2015-11-30 2017-06-08 Flagship Pioneering, Inc. Methods and compositions relating to chondrisomes
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
CA3150442A1 (en) 2019-09-02 2021-03-11 Biotest Ag Factor viii protein with increased half-life
EP3785726A1 (en) 2019-09-02 2021-03-03 Biotest AG Factor viii protein with increased half-life
WO2021165226A1 (en) 2020-02-17 2021-08-26 Biotest Ag Subcutaneous administration of factor viii
CA3197726A1 (en) 2020-10-15 2022-04-21 Simon Auslaender Nucleic acid constructs for simultaneous gene activation
CN116406425A (zh) 2020-10-15 2023-07-07 豪夫迈·罗氏有限公司 用于va rna转录的核酸构建体
WO2023060113A1 (en) 2021-10-05 2023-04-13 Regenxbio Inc. Compositions and methods for recombinant aav production
CN118202060A (zh) 2021-10-05 2024-06-14 再生生物股份有限公司 用于重组aav生产的组合物和方法
WO2023198685A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Method for determining aav genomes
WO2023227438A1 (en) 2022-05-23 2023-11-30 F. Hoffmann-La Roche Ag Raman-based method for the differentiation of aav particle serotype and aav particle loading status
WO2023232922A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024013239A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Method for producing recombinant aav particles
WO2024056561A1 (en) 2022-09-12 2024-03-21 F. Hoffmann-La Roche Ag Method for separating full and empty aav particles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6797495B2 (en) * 1996-11-05 2004-09-28 The Regents Of The University Of California Somatic cells with ablated PrP gene and methods of use
SI1533380T1 (sl) 1999-04-15 2010-03-31 Crucell Holland Bv Proizvajanje rekombinantnega proteina v človeški celici ki obsega vsaj en protein E adenovirusa
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) * 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US6369448B1 (en) * 2000-01-21 2002-04-09 Lsi Logic Corporation Vertically integrated flip chip semiconductor package
ATE514717T1 (de) * 2002-07-18 2011-07-15 Merus B V Rekombinante produktion von antikörpermischungen
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien

Also Published As

Publication number Publication date
US20070111312A1 (en) 2007-05-17
JP2009515537A (ja) 2009-04-16
WO2007056994A3 (de) 2007-11-01
WO2007056994A8 (de) 2007-07-19
KR20090114306A (ko) 2009-11-03
AU2006314931B2 (en) 2011-08-18
CN101310014A (zh) 2008-11-19
SI1948789T1 (sl) 2010-08-31
EP1948789B1 (de) 2010-06-09
ATE470702T1 (de) 2010-06-15
PT1948789E (pt) 2010-08-05
ES2345508T3 (es) 2010-09-24
IL190705A (en) 2012-04-30
DK1948789T3 (da) 2010-10-11
CA2629211A1 (en) 2007-05-24
DE102005054628A1 (de) 2007-05-24
US20150203813A1 (en) 2015-07-23
KR101244529B1 (ko) 2013-03-18
MY144034A (en) 2011-07-29
SG173947A1 (en) 2011-09-29
EP1948789A2 (de) 2008-07-30
WO2007056994A2 (de) 2007-05-24
IL190705A0 (en) 2011-08-01
JP5213719B2 (ja) 2013-06-19
CN101310014B (zh) 2012-05-30
CA2629211C (en) 2016-05-10
DE502006007198D1 (de) 2010-07-22
US8936908B2 (en) 2015-01-20
CY1110734T1 (el) 2015-06-10
AU2006314931A1 (en) 2007-05-24
US9315773B2 (en) 2016-04-19

Similar Documents

Publication Publication Date Title
SI1948789T1 (sl) Postopek za pridobivanje permanentnih humanih celičnih linij
EP3539380A3 (en) Improved cell composition and methods of making the same
MX2021015070A (es) Inmunomodulacion usando celulas madre de la placenta.
EP1942925A4 (en) METHODS OF ADMINISTERING FUSION POLYPEPTIDES IN A CELL
HK1136847A1 (en) Targeted integration into the ppp1r12c locus
UA99700C2 (ru) Способ приготовления иммортализированной человеческой клеточной линии
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
WO2009049284A3 (en) Compositions and methods for improved glycoprotein sialylation
MY160995A (en) Polypeptides with permease activity
MY185887A (en) Cell culture improvements
SG10201809901SA (en) Generating Pluripotent Cells De Novo
WO2009120762A3 (en) Human cardiovascular progenitor cells
WO2009149956A3 (en) Fusion protein and use thereof
NZ584893A (en) PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF
MX2010007716A (es) Combinacion de una proteina de fusion del anticuerpo-il-2 de anti-edb fibronectina y una molecula que se une a celulas b, progenitores de la celula b y/o sus contrapartes cancerigenas.
WO2012068317A3 (en) Methods for producing recombinant proteins
WO2012024573A3 (en) Compositions comrpising perivascular stem cells and nell-1 protein
EP2516624A4 (en) CELL LINE 3M
WO2008114673A1 (ja) ポリペプチドの製造方法
WO2010111659A8 (en) Tumor-initiating cells and methods for using same
EP3078673A3 (en) Recombinant fibrinogen
EP1963506A4 (en) COMPOSITIONS AND METHODS FOR INCREASING THE PRODUCTION OF RECOMBINANT GAMMA-CARBOXYLATED PROTEINS
PT1743029E (pt) Preparação de células
WO2009058451A3 (en) Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells
WO2012012271A3 (en) Novel glycosylated polypeptides